MARKET

CRVS

CRVS

Corvus Pharmaceu
NASDAQ
1.790
+0.030
+1.70%
Closed 16:00 03/27 EDT
OPEN
1.770
PREV CLOSE
1.760
HIGH
1.850
LOW
1.760
VOLUME
161.30K
TURNOVER
0
52 WEEK HIGH
4.190
52 WEEK LOW
0.6070
MARKET CAP
87.78M
P/E (TTM)
-3.1805
1D
5D
1M
3M
1Y
5Y
Corvus Pharmaceuticals Is Maintained at Neutral by Mizuho
Dow Jones · 15h ago
Corvus Pharmaceuticals Price Target Maintained With a $3.50/Share by Mizuho
Dow Jones · 15h ago
Mizuho Maintains Neutral on Corvus Pharma, Maintains $3.5 Price Target
Benzinga · 15h ago
Weekly Report: what happened at CRVS last week (0318-0322)?
Weekly Report · 2d ago
Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?
NASDAQ · 5d ago
Corvus Pharmaceuticals: Insider Ownership Raises Power Concentration Concerns
TipRanks · 03/21 06:01
Corvus Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Dow Jones · 03/20 11:24
Corvus Pharmaceuticals Price Target Cut to $7.00/Share From $8.00 by Oppenheimer
Dow Jones · 03/20 11:24
More
About CRVS
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.

Webull offers Corvus Pharmaceuticals Inc stock information, including NASDAQ: CRVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRVS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRVS stock methods without spending real money on the virtual paper trading platform.